Ikarian Capital, LLC Neurocrine Biosciences Inc Call Options Transaction History

Ikarian Capital, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$130.86 - $143.19 $130,860 - $143,190	1,000 New	1,000 $137,000
Q1 2022 May 13, 2022	BUY	$72.45 - $94.81 $31.1 Million - $40.7 Million	429,600 New	429,600 $40.3 Million
Q1 2021 May 17, 2021	SELL	$87.57 - $119.4 $2.08 Million - $2.83 Million	-23,700 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$86.91 - $108.33 $2.06 Million - $2.57 Million	23,700 New	23,700 $2.27 Million
Q2 2020 Aug 14, 2020	SELL	$85.09 - $130.36 $8.51 Million - $13 Million	-100,000 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$75.11 - $113.76 $6.97 Million - $10.6 Million	92,800 Added 1288.89%	100,000 $8.66 Million
Q4 2019 Jan 31, 2020	BUY	$86.8 - $118.57 $624,960 - $853,704	7,200 New	7,200 $774,000

626

94M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.